XNASSERA
Market cap263mUSD
Jan 06, Last price
8.29USD
1D
-3.72%
1Q
11.23%
IPO
-27.09%
Name
Sera Prognostics Inc
Chart & Performance
P/E
—
P/S
888.73
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
306k
+14.18%
Net income
-36m
L-18.09%
CFO
-27m
L-21.44%
Profile
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 306 14.18% | 268 226.83% | |||
Cost of revenue | 40,127 | 45,920 | |||
Unusual Expense (Income) | |||||
NOPBT | (39,821) | (45,652) | |||
NOPBT Margin | |||||
Operating Taxes | 61 | ||||
Tax Rate | |||||
NOPAT | (39,821) | (45,713) | |||
Net income | (36,242) -18.09% | (44,247) 22.13% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 1,218 | 308 | |||
BB yield | -0.65% | -0.79% | |||
| Debt | |||||
Debt current | 1,018 | 464 | |||
Long-term debt | 2,698 | 4,160 | |||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (76,204) | (99,409) | |||
| Cash flow | |||||
Cash from operating activities | (27,188) | (34,610) | |||
CAPEX | (128) | (791) | |||
Cash from investing activities | 438 | 5,551 | |||
Cash from financing activities | 752 | 5 | |||
FCF | (39,941) | (46,999) | |||
| Balance | |||||
Cash | 49,079 | 82,704 | |||
Long term investments | 30,841 | 21,329 | |||
Excess cash | 79,905 | 104,020 | |||
Stockholders' equity | (246,908) | (211,632) | |||
Invested Capital | 318,924 | 312,887 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 31,201 | 30,943 | |||
Price | 5.98 374.60% | 1.26 -81.66% | |||
Market cap | 186,580 378.55% | 38,989 -81.56% | |||
EV | 110,376 | (60,420) | |||
EBITDA | (38,921) | (44,896) | |||
EV/EBITDA | 1.35 | ||||
Interest | 55 | 61 | |||
Interest/NOPBT | |||||